1992 - Fellow of the American Association for the Advancement of Science (AAAS)
Daniel D. Von Hoff mostly deals with Internal medicine, Oncology, Cancer, Cancer research and Pharmacology. His Internal medicine research is multidisciplinary, incorporating perspectives in Gastroenterology and Surgery. His study on Cancer research also encompasses disciplines like
In his research, Human tumor is intimately related to In vivo, which falls under the overarching field of Pharmacology. The Gemcitabine study combines topics in areas such as Paclitaxel, Pancreatic cancer, Phases of clinical research and Hazard ratio. His Pharmacokinetics research includes elements of Chemotherapy and Docetaxel.
His primary areas of study are Internal medicine, Cancer, Cancer research, Oncology and Pancreatic cancer. His study ties his expertise on Gastroenterology together with the subject of Internal medicine. Daniel D. Von Hoff interconnects Tolerability and Bioinformatics in the investigation of issues within Cancer.
His research in Cancer research focuses on subjects like Pathology, which are connected to In vitro. His Oncology research includes elements of Regimen and Clinical trial, Phases of clinical research. His work deals with themes such as Tumor microenvironment, Endocrinology, Pancreas and Adenocarcinoma, which intersect with Pancreatic cancer.
Daniel D. Von Hoff mainly focuses on Internal medicine, Oncology, Pancreatic cancer, Gemcitabine and Cancer. As part of his studies on Internal medicine, Daniel D. Von Hoff often connects relevant areas like Gastroenterology. In Oncology, Daniel D. Von Hoff works on issues like Adenocarcinoma, which are connected to Pathology.
His studies deal with areas such as Cancer research, Stromal cell, Survival rate, Pancreas and Cancer-Associated Fibroblasts as well as Pancreatic cancer. His Gemcitabine research includes themes of Regimen and Fluorouracil. His research on Cancer also deals with topics like
Internal medicine, Oncology, Pancreatic cancer, Gemcitabine and Cancer are his primary areas of study. His work carried out in the field of Internal medicine brings together such families of science as Gastroenterology and Pharmacology. The study incorporates disciplines such as Clinical trial, Surgery, Toxicity, Hazard ratio and Breast cancer in addition to Oncology.
The concepts of his Pancreatic cancer study are interwoven with issues in Tumor microenvironment, Cancer research, Chemotherapy and Survival rate. His Gemcitabine research is multidisciplinary, relying on both Clinical endpoint, Fluorouracil, Paclitaxel and Phases of clinical research. His Cancer study combines topics from a wide range of disciplines, such as Immune system, Immunology, Activator and Doxorubicin.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff;Thomas Ervin;Francis P. Arena;E. Gabriela Chiorean.
The New England Journal of Medicine (2013)
Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma.
Paolo P. Provenzano;Carlos Cuevas;Amy E. Chang;Vikas K. Goel.
Cancer Cell (2012)
Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma
Daniel D. Von Hoff;Patricia M. LoRusso;Charles M. Rudin;Josina C. Reddy.
The New England Journal of Medicine (2009)
Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies
Manuel Hidalgo;Lillian L. Siu;John Nemunaitis;Jinee Rizzo.
Journal of Clinical Oncology (2001)
ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
C Heise;A Sampson-Johannes;A Williams;F McCormick.
Nature Medicine (1997)
Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449
Charles M. Rudin;Christine L. Hann;John Laterra;Robert L. Yauch.
The New England Journal of Medicine (2009)
Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile
Jeffrey Hrkach;Daniel Von Hoff;Mir Mukkaram Ali;Elizaveta Andrianova.
Science Translational Medicine (2012)
Gemcitabine Plus nab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
Daniel D. Von Hoff;Ramesh K. Ramanathan;Mitesh J. Borad;Daniel A. Laheru.
Journal of Clinical Oncology (2011)
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
Andrea Wang-Gillam;Chung-Pin Li;György Bodoky;Andrew Dean.
The Lancet (2016)
Tumor-stroma interactions in pancreatic ductal adenocarcinoma
Daruka Mahadevan;Daniel D. Von Hoff.
Molecular Cancer Therapeutics (2007)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: